The data to support SLCO1B1 variation and simvastatin-induced myopathy was sufficiently strong to incite CPIC to write guidelines on the translation of SLCO1B1 genotype into the clinical use of simvastatin [13]. The gene discussed is SLCO1B1; the disease is myopathy.